Drug Profile
Minnelide - Minneamrita Therapeutics
Alternative Names: 14-O-phosphonooxymethyltriptolide-disodium-salt; Minnelide; Minnelide-001Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator University of Minnesota
- Developer Barts and The London NHS Trust; Minneamrita Therapeutics; Queen Mary University of London; Translational Genomics Research Institute
- Class Antineoplastics; Diterpenes; Epoxy compounds; Phenanthrenes; Phosphoric acid esters
- Mechanism of Action HSP70 heat shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pancreatic cancer
- Phase I/II Acute myeloid leukaemia
- Phase I Gastric cancer
- No development reported Gastrointestinal cancer; Solid tumours
Most Recent Events
- 09 Oct 2023 Minneamrita Therapeutics terminates a phase-I trial in Acute myeloid leukaemia (Second-line therapy or greater, Late-stage disease) in USA due to dose limiting toxicity events (NCT03760523)
- 03 Oct 2022 Phase-I clinical trials in Gastric cancer (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in South Korea (PO) (NCT05566834)
- 01 Oct 2022 Phase-I clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in South Korea (PO) (NCT05557851)